Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations

Journal of the National Cancer Institute

Volumn 91, Issue 9, 1999, Pages 772-778

  Zhu, Xin Hua ^c   Shen, Yu Lei ^c   Jing, Yong Kui ^a   Cai, Xun ^c   Jia, Pei Ming ^c   Huang, Ying ^c   Tang, Wei ^c   Shi, Gui Ying ^c   Sun, Yue Ping ^c   Dai, Jie ^a   Wang, Zhen Yi ^c   Chen, Sai Juan ^c   Zhang, Ting Dong ^c   Waxman, Samuel ^a   Chen, Zhu ^c   Chen, Guo Qiang ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARSENIC TRIOXIDE; BUTHIONINE SULFOXIMINE; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; DITHIOTHREITOL; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; LYMPHOMA CELL; LYMPHOPROLIFERATIVE DISEASE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033526358     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.9.772     Document Type: Article

References (42)

1. Rew DA. Cell and molecular mechanisms of pathogenesis and treatment of cancer. Postgrad Med J 1998;74:77-88
2. Steller H. Mechanisms and genes of cellular suicide. Science 1995;267:1445-9.
3. Campana D, Coustan-Smith E, Manabe A, Buschle M, Raimondi SC, Behm FG, et al. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by over-expression of bcl-2 protein. Blood 1993;81: 1025-31.
4. Coustan-Smith E, Kitanaka A, Pui CH, NcNinch L, Evans WE, Raimindi SC, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996;87:1140-6.
5. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998;91: 3379-89.
6. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.
7. Staunton MJ, Gaffney EF. Apoptosis: basic concepts and potential significance in human cancer. Arch Pathol Lab Med 1998;122:310-9.
8. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chinese Western Med 1992;12:170-2.
9. Zhang P, Wang SY, Hu XH. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996;17:58-61.
10. Mervis J. Ancient remedy performs new tricks [news]. Science 1996;273:578.
11. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996;88:1052-61.
12. 3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-53.
13. 3+) and other metal ions on acute promyelocytic leukemia cells. Int J Hematol 1997;65:179-85.
14. Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998;91:4300-10.
15. Konig A, Wrazel L, Warrell RP Jr, Rivi R, Pandolfi PP, Jakubowski A, et al. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997;90: 562-70.
16. 3) in the treatment of acute promyelocytic leuke-mia (APL): II. Clinical efficacy and pharma7 cokinetics in relapsed patients. Blood 1997;89: 3354-60.
17. Pershagen G. The epidemiology of human arsenic exposure. In: Fowler BA, editor. Biological and environmental effects of arsenic. Oxford (U.K.): Elsevier Science Publishers; 1983. p. 199-229.
18. Van den Eugh GJ, Trask BJ, Gray JW, Langlois RG, Yu LC. Preparation and bivariate analysis of suspensions of human chromosomes. Cytometry 1985;6:92-100.
19. Marchetti P, Castedo M, Susin SA, Zamzami N, Hirsch T, Macho A, et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 1996; 184: 1155-60.
20. Kroemer G, Zamzami N. Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997;18:44-51.
21. Kumar S. ICE-like protease in apoptosis. Trends Biochem Sci 1995;20:198-204.
22. Takahashi A, Earnshaw WC. ICE-related proteases in apoptosis. Curr Opin Genet Dev 1996;6:50-5.
23. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998; 12:1383-91.
24. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin Vaffinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998;31:1-9.
25. Marzo I, Brenner C, Zamzami N, Susin SA, Beutner G, Brdiczka D, et al. The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. J Exp Med 1998;187:1261-71.
26. Falk MH, Meier T, Issels RD, Brielmeier M, Scheffer B, Bomkamm GW. Apoptosis in Burkitt lymphoma cells is prevented by promotion of cysteine uptake. Int J Cancer 1998;75: 620-5.
27. Chernyak BV. Redox regulation of the mitochondrial permeability transition pore. Biosci Rep 1997;17:293-302.
28. Zamzami N, Machetti P, Castedo M, Decaudin D. Macho A, Hirsch T, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995; 182:367-77.
29. Zamzami N, Hirsch T, Dallaporta B, Petit PX, Kroemer G. Mitochondrial implication in accidental and programmed cell death: apoptosis and necrosis. J Bioenerg Biomemb 1997;29: 185-93.
30. Rowan S, Fisher DE. Mechanisms of apoptotic cell death. Leukemia 1997;11:457-65.
31. Yager JW, Wiencke JK. Inhibition of poly(ADP-ribose) polymerase by arsenite. Mutat Res 1997;386:345-51.
32. Lynn S, Shiung JN, Gurr JR, Jan KY. Arsenite stimulates poly(ADP-ribosylation) by generation of nitric oxide. Free Radic Biol Med 1998; 24:442-9.
33. Meng Z, Meng N. Effects of inorganic arsenicals on DNA synthesis in unsensitized human blood lymphocytes in vitro. Biol Trace Elem Res 1994;42:201-8.
34. Meng Z. Effects of arsenic on DNA synthesis in human lymphocytes stimulated by phytohemagglutinin. Biol Trace Elem Res 1993;39: 73-80.
35. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268-77.
36. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, et al. Arsenic trioxide as an inducer of apoptosis and loss of PMU RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998;90: 124-33.
37. Look AT. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia [editorial]. J Natl Cancer Inst 1998;90:86-8.
38. Andre C, Guillemin MC, Zhu J, Koken MH, Quignon F, Herve L, et al. The PML and PMU RARα domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic. Exp Cell Res 1996;229:253-60.
39. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, et al. Arsenicinduced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997;94:3978-83.
40. Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol 1994;14:6858-67.
41. Le XF, Yang P, Chang KS. Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML. J Biol Chem 1996;271:130-5.
42. Ruthardt M, Orleth A, Tomassoni L, Puccetti E, Riganelli D, Alcalay M, et al The acute promyelocytic leukaemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies. Oncogene 1998;16:1945-53.